{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T19:12:31Z","timestamp":1768590751305,"version":"3.49.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2016,8,2]],"date-time":"2016-08-02T00:00:00Z","timestamp":1470096000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Academic Medical Center (AMC)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Clin Immunol"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1007\/s10875-016-0321-2","type":"journal-article","created":{"date-parts":[[2016,8,2]],"date-time":"2016-08-02T08:55:08Z","timestamp":1470128108000},"page":"656-666","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Phenotypic and Functional Comparison of Class Switch Recombination Deficiencies with a Subgroup of Common Variable Immunodeficiencies"],"prefix":"10.1007","volume":"36","author":[{"given":"Daan J.","family":"aan de Kerk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Machiel H.","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Jolles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus","family":"Warnatz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suranjith L.","family":"Seneviratne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ineke J. M.","family":"ten Berge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ester M. M.","family":"van Leeuwen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taco W.","family":"Kuijpers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,8,2]]},"reference":[{"key":"321_CR1","doi-asserted-by":"crossref","first-page":"S182","DOI":"10.1016\/j.jaci.2009.07.053","volume":"125","author":"LD Notarangelo","year":"2010","unstructured":"Notarangelo LD. Primary immunodeficiencies. J Allergy Clin Immunol. 2010;125:S182\u201394.","journal-title":"J Allergy Clin Immunol"},{"key":"321_CR2","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S1525-1578(10)60493-X","volume":"6","author":"MS Lim","year":"2004","unstructured":"Lim MS, Elenitoba-Johnson KS. The molecular pathology of primary immunodeficiencies. J Mol Diagn: JMD. 2004;6:59\u201383.","journal-title":"J Mol Diagn: JMD"},{"key":"321_CR3","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.jaci.2009.10.013","volume":"124","author":"LD Notarangelo","year":"2009","unstructured":"International Union of Immunological Societies Expert Committee on Primary, I, Notarangelo LD, Fischer A, Geha RS, Casanova JL, Chapel H, et al. Primary immunodeficiencies: 2009 update. J Allergy Clin Immunol. 2009;124:1161\u201378.","journal-title":"J Allergy Clin Immunol"},{"key":"321_CR4","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nri3466","volume":"13","author":"A Durandy","year":"2013","unstructured":"Durandy A, Kracker S, Fischer A. Primary antibody deficiencies. Nat Rev Immunol. 2013;13:519\u201333.","journal-title":"Nat Rev Immunol"},{"key":"321_CR5","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.jaci.2010.02.018","volume":"125","author":"AM Vale","year":"2010","unstructured":"Vale AM, Schroeder Jr HW. Clinical consequences of defects in B-cell development. J Allergy Clin Immunol. 2010;125:778\u201387.","journal-title":"J Allergy Clin Immunol"},{"key":"321_CR6","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.0105-2896.2005.00222.x","volume":"203","author":"A Durandy","year":"2005","unstructured":"Durandy A, Revy P, Imai K, Fischer A. Hyper-immunoglobulin M syndromes caused by intrinsic B-lymphocyte defects. Immunol Rev. 2005;203:67\u201379.","journal-title":"Immunol Rev"},{"key":"321_CR7","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1365-2141.2010.08077.x","volume":"149","author":"EG Davies","year":"2010","unstructured":"Davies EG, Thrasher AJ. Update on the hyper immunoglobulin M syndromes. Br J Haematol. 2010;149:167\u201380.","journal-title":"Br J Haematol"},{"key":"321_CR8","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/361539a0","volume":"361","author":"U Korthauer","year":"1993","unstructured":"Korthauer U, Graf D, Mages HW, Briere F, Padayachee M, Malcolm S, et al. Defective expression of T-cell CD40 ligand causes X-linked immunodeficiency with hyper-IgM. Nature. 1993;361:539\u201341.","journal-title":"Nature"},{"key":"321_CR9","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0092-8674(00)00079-9","volume":"102","author":"P Revy","year":"2000","unstructured":"Revy P, Muto T, Levy Y, Geissmann F, Plebani A, Sanal O, et al. Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2). Cell. 2000;102:565\u201375.","journal-title":"Cell"},{"key":"321_CR10","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.clim.2005.02.003","volume":"115","author":"K Imai","year":"2005","unstructured":"Imai K, Zhu Y, Revy P, Morio T, Mizutani S, Fischer A, et al. Analysis of class switch recombination and somatic hypermutation in patients affected with autosomal dominant hyper-IgM syndrome type 2. Clin Immunol. 2005;115:277\u201385.","journal-title":"Clin Immunol"},{"key":"321_CR11","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/ni974","volume":"4","author":"K Imai","year":"2003","unstructured":"Imai K, Slupphaug G, Lee WI, Revy P, Nonoyama S, Catalan N, et al. Human uracil-DNA glycosylase deficiency associated with profoundly impaired immunoglobulin class-switch recombination. Nat Immunol. 2003;4:1023\u20138.","journal-title":"Nat Immunol"},{"key":"321_CR12","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1182\/blood-2007-11-124545","volume":"112","author":"H Chapel","year":"2008","unstructured":"Chapel H, Lucas M, Lee M, Bjorkander J, Webster D, Grimbacher B, et al. Common variable immunodeficiency disorders: division into distinct clinical phenotypes. Blood. 2008;112:277\u201386.","journal-title":"Blood"},{"key":"321_CR13","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1007\/s10875-010-9424-3","volume":"30","author":"G Mouillot","year":"2010","unstructured":"Mouillot G, Carmagnat M, Gerard L, Garnier JL, Fieschi C, Vince N, et al. B-cell and T-cell phenotypes in CVID patients correlate with the clinical phenotype of the disease. J Clin Immunol. 2010;30:746\u201355.","journal-title":"J Clin Immunol"},{"key":"321_CR14","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1006\/clim.1999.4725","volume":"92","author":"C Cunningham-Rundles","year":"1999","unstructured":"Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol. 1999;92:34\u201348.","journal-title":"Clin Immunol"},{"key":"321_CR15","doi-asserted-by":"crossref","first-page":"5012","DOI":"10.4049\/jimmunol.1201807","volume":"190","author":"DJ Kerk aan de","year":"2013","unstructured":"aan de Kerk DJ, Jansen MH, ten Berge IJ, van Leeuwen EM, Kuijpers TW. Identification of B cell defects using age-defined reference ranges for in vivo and in vitro B cell differentiation. J Immunol. 2013;190:5012\u20139.","journal-title":"J Immunol"},{"key":"321_CR16","doi-asserted-by":"crossref","first-page":"6814","DOI":"10.1182\/blood-2011-06-361881","volume":"118","author":"GJ Driessen","year":"2011","unstructured":"Driessen GJ, van Zelm MC, van Hagen PM, Hartwig NG, Trip M, Warris A, et al. B-cell replication history and somatic hypermutation status identify distinct pathophysiologic backgrounds in common variable immunodeficiency. Blood. 2011;118:6814\u201323.","journal-title":"Blood"},{"key":"321_CR17","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1182\/blood-2007-06-091744","volume":"111","author":"C Wehr","year":"2008","unstructured":"Wehr C, Kivioja T, Schmitt C, Ferry B, Witte T, Eren E, et al. The EUROclass trial: defining subgroups in common variable immunodeficiency. Blood. 2008;111:77\u201385.","journal-title":"Blood"},{"issue":"1360\u20131363","key":"321_CR18","volume":"128","author":"TW Kuijpers","year":"2011","unstructured":"Kuijpers TW, Baars PA, Aan de Kerk DJ, Jansen MH, Derks IA, Bredius RG, et al. A novel mutation in CD132 causes X-CID with defective T-cell activation and impaired humoral reactivity. J Allergy Clin Immunol. 2011;128(1360\u20131363), e1364.","journal-title":"J Allergy Clin Immunol"},{"key":"321_CR19","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1749-6632.2011.06278.x","volume":"1246","author":"MA Berkowska","year":"2011","unstructured":"Berkowska MA, van der Burg M, van Dongen JJ, van Zelm MC. Checkpoints of B cell differentiation: visualizing Ig-centric processes. Ann N Y Acad Sci. 2011;1246:11\u201325.","journal-title":"Ann N Y Acad Sci"},{"key":"321_CR20","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2008-02-078071","volume":"112","author":"TW LeBien","year":"2008","unstructured":"LeBien TW, Tedder TF. B lymphocytes: how they develop and function. Blood. 2008;112:1570\u201380.","journal-title":"Blood"},{"key":"321_CR21","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1182\/blood-2002-11-3569","volume":"101","author":"NL Bernasconi","year":"2003","unstructured":"Bernasconi NL, Onai N, Lanzavecchia A. A role for Toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells. Blood. 2003;101:4500\u20134.","journal-title":"Blood"},{"key":"321_CR22","doi-asserted-by":"crossref","first-page":"6824","DOI":"10.1182\/blood-2011-06-362533","volume":"118","author":"M Recher","year":"2011","unstructured":"Recher M, Berglund LJ, Avery DT, Cowan MJ, Gennery AR, Smart J, et al. IL-21 is the primary common gamma chain-binding cytokine required for human B-cell differentiation in vivo. Blood. 2011;118:6824\u201335.","journal-title":"Blood"},{"key":"321_CR23","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1126\/science.1243292","volume":"342","author":"I Angulo","year":"2013","unstructured":"Angulo I, Vadas O, Garcon F, Banham-Hall E, Plagnol V, Leahy TR, et al. Phosphoinositide 3-kinase delta gene mutation predisposes to respiratory infection and airway damage. Science. 2013;342:866\u201371.","journal-title":"Science"},{"key":"321_CR24","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/ni.2771","volume":"15","author":"CL Lucas","year":"2014","unstructured":"Lucas CL, Kuehn HS, Zhao F, Niemela JE, Deenick EK, Palendira U, et al. Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110delta result in T cell senescence and human immunodeficiency. Nat Immunol. 2014;15:88\u201397.","journal-title":"Nat Immunol"},{"key":"321_CR25","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1007\/s10875-014-0012-9","volume":"34","author":"MC Crank","year":"2014","unstructured":"Crank MC, Grossman JK, Moir S, Pittaluga S, Buckner CM, Kardava L, et al. Mutations in PIK3CD can cause hyper IgM syndrome (HIGM) associated with increased cancer susceptibility. J Clin Immunol. 2014;34:272\u20136.","journal-title":"J Clin Immunol"},{"key":"321_CR26","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1084\/jem.186.9.1407","volume":"186","author":"D Hamann","year":"1997","unstructured":"Hamann D, Baars PA, Rep MH, Hooibrink B, Kerkhof-Garde SR, Klein MR, et al. Phenotypic and functional separation of memory and effector human CD8+ T cells. J Exp Med. 1997;186:1407\u201318.","journal-title":"J Exp Med"},{"key":"321_CR27","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.cell.2015.03.020","volume":"161","author":"S Zheng","year":"2015","unstructured":"Zheng S, Vuong BQ, Vaidyanathan B, Lin JY, Huang FT, Chaudhuri J. Non-coding RNA generated following lariat debranching mediates targeting of AID to DNA. Cell. 2015;161:762\u201373.","journal-title":"Cell"},{"key":"321_CR28","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S0092-8674(00)00078-7","volume":"102","author":"M Muramatsu","year":"2000","unstructured":"Muramatsu M, Kinoshita K, Fagarasan S, Yamada S, Shinkai Y, Honjo T. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell. 2000;102:553\u201363.","journal-title":"Cell"},{"key":"321_CR29","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.3324\/haematol.2012.077511","volume":"98","author":"TW Kuijpers","year":"2013","unstructured":"Kuijpers TW, van Leeuwen EM, Barendregt BH, Klarenbeek P, aan de Kerk DJ, Baars PA, et al. A reversion of an IL2RG mutation in combined immunodeficiency providing competitive advantage to the majority of CD8+ T cells. Haematologica. 2013;98:1030\u20138.","journal-title":"Haematologica"},{"key":"321_CR30","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.4049\/jimmunol.154.4.1560","volume":"154","author":"A Durandy","year":"1995","unstructured":"Durandy A, De Saint Basile G, Lisowska-Grospierre B, Gauchat JF, Forveille M, Kroczek RA, et al. Undetectable CD40 ligand expression on T cells and low B cell responses to CD40 binding agonists in human newborns. J Immunol. 1995;154:1560\u20138.","journal-title":"J Immunol"},{"key":"321_CR31","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1182\/blood-2010-05-287821","volume":"117","author":"S Zhang","year":"2011","unstructured":"Zhang S, Readinger JA, DuBois W, Janka-Junttila M, Robinson R, Pruitt M, et al. Constitutive reductions in mTOR alter cell size, immune cell development, and antibody production. Blood. 2011;117:1228\u201338.","journal-title":"Blood"},{"key":"321_CR32","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1128\/MCB.01187-14","volume":"35","author":"S Benhamron","year":"2015","unstructured":"Benhamron S, Pattanayak SP, Berger M, Tirosh B. mTOR activation promotes plasma cell differentiation and bypasses XBP-1 for immunoglobulin secretion. Mol Cell Biol. 2015;35:153\u201366.","journal-title":"Mol Cell Biol"},{"key":"321_CR33","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1002\/eji.201041336","volume":"41","author":"S Benhamron","year":"2011","unstructured":"Benhamron S, Tirosh B. Direct activation of mTOR in B lymphocytes confers impairment in B-cell maturation andloss of marginal zone B cells. Eur J Immunol. 2011;41:2390\u20136.","journal-title":"Eur J Immunol"},{"key":"321_CR34","doi-asserted-by":"crossref","first-page":"228","DOI":"10.3389\/fimmu.2012.00228","volume":"3","author":"JJ Limon","year":"2012","unstructured":"Limon JJ, Fruman DA. Akt and mTOR in B cell activation and differentiation. Front Immunol. 2012;3:228.","journal-title":"Front Immunol"},{"key":"321_CR35","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/nm.3746","volume":"20","author":"D Schubert","year":"2014","unstructured":"Schubert D, Bode C, Kenefeck R, Hou TZ, Wing JB, Kennedy A, et al. Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations. Nat Med. 2014;20:1410\u20136.","journal-title":"Nat Med"},{"key":"321_CR36","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1126\/science.1255904","volume":"345","author":"HS Kuehn","year":"2014","unstructured":"Kuehn HS, Ouyang W, Lo B, Deenick EK, Niemela JE, Avery DT, et al. Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. Science. 2014;345:1623\u20137.","journal-title":"Science"},{"key":"321_CR37","first-page":"162","volume":"5","author":"W Al-Herz","year":"2014","unstructured":"Al-Herz W, Bousfiha A, Casanova JL, Chatila T, Conley ME, Cunningham-Rundles C, et al. Primary immunodeficiency diseases: an update on the classification from the international union of immunological societies expert committee for primary immunodeficiency. Front Immunol. 2014;5:162.","journal-title":"Front Immunol"}],"container-title":["Journal of Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-016-0321-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10875-016-0321-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-016-0321-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T12:55:41Z","timestamp":1692449741000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10875-016-0321-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,2]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["321"],"URL":"https:\/\/doi.org\/10.1007\/s10875-016-0321-2","relation":{},"ISSN":["0271-9142","1573-2592"],"issn-type":[{"value":"0271-9142","type":"print"},{"value":"1573-2592","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,2]]}}}